A new approach to cancer treatment - inhibition of protein degradation June 27, 2016 Source: Bio Valley June 1, 2016 / Bio Valley BIOON / -- De Bruin, a researcher from the University of Leiden in the Netherlands, is working on the chemical and biological properties of the proteasome. He said that the proteasome is a way to cut proteins into small ones. The fragmentation degradation plant, which is highly active, is also a key substance for cells to clear damaged proteins. Proteasome inhibitors protect against cancer Many times scientists use a variety of methods to inhibit the activity of the proteasome, thereby inhibiting the development of autoimmune diseases and cancer. De Bruin explains that in a particular type of cancer, the level of protein production in cells is higher than in normal cells. By inhibiting the activity of the proteasome, it can block the degradation of the protein, causing the protein to clump and accumulate, thereby killing the cancer cells. Proteasome inhibitors are currently available on the market for the treatment of Carle's disease (multiple myeloma). The advantage of proteasome inhibitors is that they can affect the activity of the proteasome, which is not only manifested in cancer cells, but also in performance. In healthy cells, this suggests that the proteasome may have certain side effects. Chemical determination method Researchers have studied various methods for specifically inhibiting the activity of proteasomes. Now researchers De Bruin have devised a method to simultaneously measure all activities of the proteasome, a cylindrical structure. There are six different active centers that can act as scissors to selectively cleave proteins. Bruin says, I have created special molecules that can bind these active centers, and now we are studying these six active centers. Activity. Special inhibitor Subsequently, the researcher Bruin designed a molecule that specifically binds to the active center of the proteasome, but the researchers' goal is to inhibit the activity of the proteasome. They developed special inhibitors for each active center, and these inhibitors are now It has been used to study the role of each active center in different diseases, such as cancer and autoimmune diseases. The results of relevant experiments indicate that researchers may be able to kill leukemia cells by selectively blocking two active centers. hope Now researcher De Bruin has published research results in several research journals, and his tools have been widely used. Of course, more in-depth research is needed to explain the mechanism of proteasome work, and The role played in cancer and autoimmune diseases. Of course, scientists have also gained more research clues by carefully studying these active centers. Bruin believes that selectively inhibiting the different active centers of the proteasome may help develop more novel therapeutic therapies later. Rictron Industrial Co., Ltd , https://www.szrictron.com
A new approach to cancer treatment - inhibition of protein degradation